Astrazeneca Ab patent expiration

1. Breztri Aerosphere patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703806 ASTRAZENECA AB Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents
May, 2030

(5 years from now)

US8808713 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
May, 2030

(5 years from now)

US8324266 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(5 years from now)

US9415009 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(5 years from now)

US10716753 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
May, 2030

(5 years from now)

US9463161 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
May, 2030

(5 years from now)

US8815258 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents
Mar, 2031

(6 years from now)

US11331442 ASTRAZENECA AB Drug delivery systems and related methods
Oct, 2038

(14 years from now)

US11833292 ASTRAZENECA AB Drug delivery systems and related methods
Oct, 2038

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jul 23, 2023

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 23 July, 2020

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED

More Information on Dosage

BREZTRI AEROSPHERE family patents

Family Patents

2. Bydureon patent expiration

BYDUREON's oppositions filed in EPO
BYDUREON IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 22 days from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5424286 ASTRAZENECA AB Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
Dec, 2016

(7 years ago)

US6858576 ASTRAZENECA AB Methods for regulating gastrointestinal motility
Jan, 2017

(7 years ago)

US6956026 ASTRAZENECA AB Use of exendins for the reduction of food intake
Jan, 2018

(6 years ago)

US7741269 ASTRAZENECA AB Exendins and exendin agonists for weight reduction and obesity
Jan, 2018

(6 years ago)

US6872700 ASTRAZENECA AB Methods for glucagon suppression
Jan, 2020

(4 years ago)

US6667061 ASTRAZENECA AB Preparation of injectable suspensions having improved injectability
May, 2020

(4 years ago)

US6495164 ASTRAZENECA AB Preparation of injectable suspensions having improved injectability
May, 2020

(4 years ago)

US6479065 ASTRAZENECA AB Process for the preparation of polymer-based sustained release compositions
Aug, 2020

(4 years ago)

US6936590 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US9198925 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Oct, 2020

(3 years ago)

US7223440 ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Aug, 2021

(3 years ago)

US7223440

(Pediatric)

ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Mar, 2022

(2 years ago)

US6824822 ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Oct, 2022

(1 year, 11 months ago)

US6824822

(Pediatric)

ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Apr, 2023

(1 year, 5 months ago)

US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(4 months ago)

US7563871 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(4 months ago)

US7563871

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(a month from now)

US9238076

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(a month from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(6 months from now)

US7612176 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(6 months from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(6 months from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(9 months from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(1 year, 1 month from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(1 year, 1 month from now)

US7612176

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(1 year, 1 month from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Dec, 2025

(1 year, 3 months from now)

US6515117

(Pediatric)

ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Apr, 2026

(1 year, 6 months from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(1 year, 11 months from now)

US9884092 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(1 year, 11 months from now)

US8906851 ASTRAZENECA AB Method for treating diabetes
Aug, 2026

(1 year, 11 months from now)

US9884092

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(2 years from now)

US8329648

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(2 years from now)

US8906851

(Pediatric)

ASTRAZENECA AB Method for treating diabetes
Feb, 2027

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(2 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2027

(3 years from now)

US8216180 ASTRAZENECA AB Administering apparatus with functional drive element
Jan, 2028

(3 years from now)

US8221786 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8439864 ASTRAZENECA AB Device for administering fluid from a multi-chamber ampoule in incremental steps
Mar, 2028

(3 years from now)

US7851502 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Aug, 2028

(3 years from now)

US8361972

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Sep, 2028

(4 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 27, 2015
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
M(M-224) Apr 02, 2021
M(M-240) Feb 15, 2022
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: Treating type 2 diabetes mellitus with exenatide by stimulating insulin release; Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4; Reducing food in...

Dosage: FOR SUSPENSION, EXTENDED RELEASE

More Information on Dosage

BYDUREON family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Bydureon Bcise patent expiration

BYDUREON BCISE's oppositions filed in EPO
BYDUREON BCISE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 22 days from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7741269 ASTRAZENECA AB Exendins and exendin agonists for weight reduction and obesity
Jan, 2018

(6 years ago)

US6956026 ASTRAZENECA AB Use of exendins for the reduction of food intake
Jan, 2018

(6 years ago)

US6872700 ASTRAZENECA AB Methods for glucagon suppression
Jan, 2020

(4 years ago)

US6667061 ASTRAZENECA AB Preparation of injectable suspensions having improved injectability
May, 2020

(4 years ago)

US6479065 ASTRAZENECA AB Process for the preparation of polymer-based sustained release compositions
Aug, 2020

(4 years ago)

US9198925 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Oct, 2020

(3 years ago)

US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US6936590 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US7223440 ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Aug, 2021

(3 years ago)

US7223440

(Pediatric)

ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Mar, 2022

(2 years ago)

US6824822 ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Oct, 2022

(1 year, 11 months ago)

US6824822

(Pediatric)

ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Apr, 2023

(1 year, 5 months ago)

US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(4 months ago)

US7563871 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(4 months ago)

US7563871

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(a month from now)

US9238076

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(a month from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(6 months from now)

US7612176 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(6 months from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(6 months from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(9 months from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(1 year, 1 month from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(1 year, 1 month from now)

US7612176

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(1 year, 1 month from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Dec, 2025

(1 year, 3 months from now)

US6515117

(Pediatric)

ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Apr, 2026

(1 year, 6 months from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(1 year, 11 months from now)

US9884092 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(1 year, 11 months from now)

US8906851 ASTRAZENECA AB Method for treating diabetes
Aug, 2026

(1 year, 11 months from now)

US8906851

(Pediatric)

ASTRAZENECA AB Method for treating diabetes
Feb, 2027

(2 years from now)

US9884092

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(2 years from now)

US8329648

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(2 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2027

(3 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8361972

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Sep, 2028

(4 years from now)

US8895033 ASTRAZENECA AB Sustained release formulations using non-aqueous carriers
Oct, 2030

(6 years from now)

US8895033

(Pediatric)

ASTRAZENECA AB Sustained release formulations using non-aqueous carriers
Apr, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 20, 2020
M(M-240) Feb 15, 2022
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: Reductions in body weight are observed with exenatide; Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4; As an adjunct to diet and exercise to imp...

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

BYDUREON BCISE family patents

Family Patents

4. Bydureon Pen patent expiration

BYDUREON PEN's oppositions filed in EPO
BYDUREON PEN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 22 days from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5424286 ASTRAZENECA AB Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
Dec, 2016

(7 years ago)

US6858576 ASTRAZENECA AB Methods for regulating gastrointestinal motility
Jan, 2017

(7 years ago)

US7741269 ASTRAZENECA AB Exendins and exendin agonists for weight reduction and obesity
Jan, 2018

(6 years ago)

US6956026 ASTRAZENECA AB Use of exendins for the reduction of food intake
Jan, 2018

(6 years ago)

US6872700 ASTRAZENECA AB Methods for glucagon suppression
Jan, 2020

(4 years ago)

US6495164 ASTRAZENECA AB Preparation of injectable suspensions having improved injectability
May, 2020

(4 years ago)

US6667061 ASTRAZENECA AB Preparation of injectable suspensions having improved injectability
May, 2020

(4 years ago)

US6479065 ASTRAZENECA AB Process for the preparation of polymer-based sustained release compositions
Aug, 2020

(4 years ago)

US6936590 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US9198925 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Oct, 2020

(3 years ago)

US7223440 ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Aug, 2021

(3 years ago)

US7223440

(Pediatric)

ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Mar, 2022

(2 years ago)

US6824822 ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Oct, 2022

(1 year, 11 months ago)

US6824822

(Pediatric)

ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Apr, 2023

(1 year, 5 months ago)

US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(4 months ago)

US7563871 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(4 months ago)

US7563871

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(a month from now)

US9238076

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(a month from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(6 months from now)

US7612176 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(6 months from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(6 months from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(9 months from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(1 year, 1 month from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(1 year, 1 month from now)

US7612176

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(1 year, 1 month from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Dec, 2025

(1 year, 3 months from now)

US6515117

(Pediatric)

ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Apr, 2026

(1 year, 6 months from now)

US8906851 ASTRAZENECA AB Method for treating diabetes
Aug, 2026

(1 year, 11 months from now)

US9884092 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(1 year, 11 months from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(1 year, 11 months from now)

US8906851

(Pediatric)

ASTRAZENECA AB Method for treating diabetes
Feb, 2027

(2 years from now)

US8329648

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(2 years from now)

US9884092

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(2 years from now)

US8758292 ASTRAZENECA AB Administering apparatus with functional drive element
Nov, 2027

(3 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2027

(3 years from now)

US8216180 ASTRAZENECA AB Administering apparatus with functional drive element
Jan, 2028

(3 years from now)

US8221786 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US9320853 ASTRAZENECA AB Method for administering a fluid active substance from a multi-chamber ampoule
Mar, 2028

(3 years from now)

US8439864 ASTRAZENECA AB Device for administering fluid from a multi-chamber ampoule in incremental steps
Mar, 2028

(3 years from now)

US8758292

(Pediatric)

ASTRAZENECA AB Administering apparatus with functional drive element
May, 2028

(3 years from now)

US8216180

(Pediatric)

ASTRAZENECA AB Administering apparatus with functional drive element
Jul, 2028

(3 years from now)

US7851502 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Aug, 2028

(3 years from now)

US8361972

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Sep, 2028

(4 years from now)

US8439864

(Pediatric)

ASTRAZENECA AB Device for administering fluid from a multi-chamber ampoule in incremental steps
Sep, 2028

(4 years from now)

US9320853

(Pediatric)

ASTRAZENECA AB Method for administering a fluid active substance from a multi-chamber ampoule
Sep, 2028

(4 years from now)

US8827963 ASTRAZENECA AB Administering device with holding mechanism
Feb, 2029

(4 years from now)

US8690837 ASTRAZENECA AB Mixing device for a two-chamber ampoule
May, 2029

(4 years from now)

US8827963

(Pediatric)

ASTRAZENECA AB Administering device with holding mechanism
Aug, 2029

(4 years from now)

US8690837

(Pediatric)

ASTRAZENECA AB Mixing device for a two-chamber ampoule
Nov, 2029

(5 years from now)

US8998876 ASTRAZENECA AB Ampoule comprising an ampoule holder
Jan, 2030

(5 years from now)

US8721615 ASTRAZENECA AB Ampoule comprising an ampoule holder
Jan, 2030

(5 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(5 years from now)

US8998876

(Pediatric)

ASTRAZENECA AB Ampoule comprising an ampoule holder
Jul, 2030

(5 years from now)

US8721615

(Pediatric)

ASTRAZENECA AB Ampoule comprising an ampoule holder
Jul, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 27, 2015
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
M(M-224) Apr 02, 2021
M(M-240) Feb 15, 2022
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: Treating type 2 diabetes mellitus with exenatide by stimulating insulin release; Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4; Reductions in bo...

Dosage: FOR SUSPENSION, EXTENDED RELEASE

More Information on Dosage

BYDUREON PEN family patents

Family Patents

5. Byetta patent expiration

BYETTA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5424286 ASTRAZENECA AB Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
Dec, 2016

(7 years ago)

US6858576 ASTRAZENECA AB Methods for regulating gastrointestinal motility
Jan, 2017

(7 years ago)

US7297761 ASTRAZENECA AB Pharmaceutical compositions containing exendins
Oct, 2017

(6 years ago)

US7521423 ASTRAZENECA AB Exendin pharmaceutical compositions
Oct, 2017

(6 years ago)

US7741269 ASTRAZENECA AB Exendins and exendin agonists for weight reduction and obesity
Jan, 2018

(6 years ago)

US6956026 ASTRAZENECA AB Use of exendins for the reduction of food intake
Jan, 2018

(6 years ago)

US6872700 ASTRAZENECA AB Methods for glucagon suppression
Jan, 2020

(4 years ago)

US6902744 ASTRAZENECA AB Exendin agonist formulations and methods of administration thereof
Jan, 2020

(4 years ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-113) Oct 19, 2014
M(M-111) Oct 19, 2014
M(M-148) Nov 24, 2017
M(M-232) Nov 04, 2024

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 28 April, 2005

Treatment: Treating type 2 diabetes mellitus with exenatide by stimulating insulin release; Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4; Use of exenatide...

Dosage: INJECTABLE

How can I launch a generic of BYETTA before it's drug patent expiration?
More Information on Dosage

BYETTA family patents

Family Patents

6. Farxiga patent expiration

FARXIGA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 22 days from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6936590 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US9198925 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Oct, 2020

(3 years ago)

US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(4 months ago)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(6 months from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(6 months from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(9 months from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(1 year, 1 month from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(1 year, 1 month from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Dec, 2025

(1 year, 3 months from now)

US6515117

(Pediatric)

ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Apr, 2026

(1 year, 6 months from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(1 year, 11 months from now)

US8906851 ASTRAZENECA AB Method for treating diabetes
Aug, 2026

(1 year, 11 months from now)

US8906851

(Pediatric)

ASTRAZENECA AB Method for treating diabetes
Feb, 2027

(2 years from now)

US8329648

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(2 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2027

(3 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8221786 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US7851502 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Aug, 2028

(3 years from now)

US8716251

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Sep, 2028

(4 years from now)

US8221786

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Sep, 2028

(4 years from now)

US8361972

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Sep, 2028

(4 years from now)

US7851502

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Feb, 2029

(4 years from now)

US8721615 ASTRAZENECA AB Ampoule comprising an ampoule holder
Jan, 2030

(5 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(5 years from now)

US7919598

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2030

(5 years from now)

US8721615

(Pediatric)

ASTRAZENECA AB Ampoule comprising an ampoule holder
Jul, 2030

(5 years from now)

US8685934

(Pediatric)

ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
Nov, 2030

(6 years from now)

US11826376 ASTRAZENECA AB Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same
Jul, 2039

(14 years from now)

US11826376

(Pediatric)

ASTRAZENECA AB Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same
Jan, 2040

(15 years from now)

US11903955 ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction
Mar, 2040

(15 years from now)

US10973836 ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction
Mar, 2040

(15 years from now)

US10973836

(Pediatric)

ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction
Sep, 2040

(16 years from now)

US11903955

(Pediatric)

ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction
Sep, 2040

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-157) Mar 11, 2018
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-212) Oct 20, 2020
M(M-238) Feb 22, 2022
New Indication(I-841) Oct 18, 2022
New Indication(I-834) May 05, 2023
New Indication(I-857) Apr 30, 2024
M(M-298) May 08, 2026
New Patient Population(NPP) Jun 12, 2027
Pediatric Exclusivity(PED) Dec 12, 2027

Drugs and Companies using DAPAGLIFLOZIN ingredient

NCE-1 date: 12 December, 2026

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in combination with exenatide; Reducing hba1c in a human in need thereof in combination with a sustained-release compositio...

Dosage: TABLET

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

7. Kombiglyze Xr patent expiration

KOMBIGLYZE XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6395767 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Feb, 2021

(3 years ago)

USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(1 year, 1 month ago)

US9339472 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(9 months from now)

US8628799 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(9 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 31, 2014
M(M-134) May 24, 2016
M(M-175) Apr 05, 2019
M(M-198) Feb 27, 2020

Drugs and Companies using METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient

NCE-1 date: 31 July, 2013

Market Authorisation Date: 05 November, 2010

Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of KOMBIGLYZE XR before it's drug patent expiration?
More Information on Dosage

KOMBIGLYZE XR family patents

Family Patents

8. Onglyza patent expiration

ONGLYZA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6395767 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Feb, 2021

(3 years ago)

USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(1 year, 1 month ago)

US7951400 ASTRAZENECA AB Coated tablet formulation and method
Nov, 2028

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 31, 2014
M(M-108) Dec 16, 2014
M(M-134) May 24, 2016
M(M-175) Apr 05, 2019
M(M-198) Feb 27, 2020

Drugs and Companies using SAXAGLIPTIN HYDROCHLORIDE ingredient

NCE-1 date: 31 July, 2013

Market Authorisation Date: 31 July, 2009

Treatment: Method for treating type ii diabetes by administering saxagliptin

Dosage: TABLET

How can I launch a generic of ONGLYZA before it's drug patent expiration?
More Information on Dosage

ONGLYZA family patents

Family Patents

9. Qtern patent expiration

QTERN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(1 year, 1 month ago)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 22 days from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9198925 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Oct, 2020

(3 years ago)

US6936590 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US8628799 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(9 months from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(2 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8221786 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-175) Apr 05, 2019
New Combination(NC) Feb 27, 2020
New Strength(NS) May 02, 2022
New Indication(I-804) May 02, 2022

Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient

NCE-1 date: 08 January, 2018

Market Authorisation Date: 02 May, 2019

Treatment: Treatment of type 2 diabetes mellitus; Method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin

Dosage: TABLET

How can I launch a generic of QTERN before it's drug patent expiration?
More Information on Dosage

QTERN family patents

Family Patents

10. Qternmet Xr patent expiration

QTERNMET XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(1 year, 1 month ago)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 22 days from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6936590 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US9198925 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Oct, 2020

(3 years ago)

US8628799 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(9 months from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(2 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US9616028 ASTRAZENECA AB Bilayer tablet formulations
Nov, 2030

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 02, 2022

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient

Market Authorisation Date: 02 May, 2019

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

QTERNMET XR family patents

Family Patents

11. Symlin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6608029 ASTRAZENECA AB Methods for regulating gastrointestinal motility
Sep, 2013

(11 years ago)

US5814600 ASTRAZENECA AB Method and composition for treatment of insulin requiring mammals
Sep, 2015

(8 years ago)

US6114304 ASTRAZENECA AB Methods for regulating gastrointestinal motility
Sep, 2017

(7 years ago)

US5686411 ASTRAZENECA AB Amylin agonist peptides and uses therefor
Mar, 2019

(5 years ago)




Drugs and Companies using PRAMLINTIDE ACETATE ingredient

Market Authorisation Date: 25 September, 2007

Treatment: Treatment of diabetes with an amylin agonist; Treatment of a mammal having a need of or reduced ability to produce insulin with an insulin and an amylin such as pramlintide; Treatment of diabetes with...

Dosage: INJECTABLE

More Information on Dosage

SYMLIN family patents

Family Patents

12. Wainua (autoinjector) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8101743 ASTRAZENECA AB Modulation of transthyretin expression
Apr, 2025

(6 months from now)

US9127276 ASTRAZENECA AB Conjugated antisense compounds and their use
May, 2034

(9 years from now)

US9181549 ASTRAZENECA AB Conjugated antisense compounds and their use
May, 2034

(9 years from now)

US10683499 ASTRAZENECA AB Compositions and methods for modulating TTR expression
Aug, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 21, 2028
Orphan Drug Exclusivity(ODE-461) Dec 21, 2030

Drugs and Companies using EPLONTERSEN SODIUM ingredient

NCE-1 date: 22 December, 2027

Market Authorisation Date: 21 December, 2023

Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis

Dosage: SOLUTION

More Information on Dosage

WAINUA (AUTOINJECTOR) family patents

Family Patents

13. Xigduo Xr patent expiration

XIGDUO XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 22 days from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6936590 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US9198925 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Oct, 2020

(3 years ago)

US6515117

(Pediatric)

ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Apr, 2026

(1 year, 6 months from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(2 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2027

(3 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(5 years from now)

US7919598

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2030

(5 years from now)

US9616028 ASTRAZENECA AB Bilayer tablet formulations
Nov, 2030

(6 years from now)

US8685934

(Pediatric)

ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
Nov, 2030

(6 years from now)

US9616028

(Pediatric)

ASTRAZENECA AB Bilayer tablet formulations
May, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-238) Feb 22, 2022
New Indication(I-841) Oct 18, 2022
New Patient Population(NPP) Jun 12, 2027
Pediatric Exclusivity(PED) Dec 12, 2027

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 12 December, 2026

Market Authorisation Date: 28 July, 2017

Treatment: Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazo...

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of XIGDUO XR before it's drug patent expiration?
More Information on Dosage

XIGDUO XR family patents

Family Patents